(Information sent by the signatory company)

-Significant advances in the COVID-19 recombinant protein trivalent vaccine against subvariants such as XBB.1.5 and BA.5 from WestVac Biopharma

CHENGDU, China, Feb. 21, 2023 /PRNewswire/ — Recently, with the support of China’s National Key R&D Program, following the approval of the COVID-19 recombinant variant (Sf9 cell) vaccine clinical trial approved by the NMPA, WestVac Biopharma (Guangzhou) Co. Ltd. (hereinafter referred to as “WestVac Biopharma (Guangzhou)”) has made significant progress in the development of the COVID-19 recombinant protein trivalent vaccine against the latest prevalent subvariants, including XBB .1.5 and BA.5, which is one of the first recombinant protein trivalent vaccines directed against XBB.1.5 worldwide.

Taking advantage of the rapid response of the internationally advanced insect cell expression platform in the production of recombinant protein vaccines, WestVac Biopharma (Guangzhou) has constructed the vector within one month, and has produced the trivalent recombinant protein vaccine of high purity and quality for human use. It is a fully synthetic vaccine. The vaccine subunit antigen is precisely engineered from the structure of the XBB.1.5 and BA.5 subvariant S-RBD and HR proteins, and can self-assemble into stable trimeric protein particles. The study revealed that the vaccine induced high titers of neutralizing antibodies against Omicron XBB.1.5, BQ.1, BF.7, BA.5, BA.2.75 and other subvariants, suggesting that it is a COVID-19 vaccine of broad spectrum against multiple sub-variants prevalent at home and abroad, such as XBB.1.5, BQ.1, BF.7 and BA.5. Currently, WestVac Biopharma is actively collaborating with national authorities and striving to meet national recombinant protein trivalent vaccine approval requirements as soon as possible. The goal is to use the power of WestVac Biopharma to help in the fight against new variants of coronavirus!

WestVac Biopharma (Guangzhou) is a wholly-owned subsidiary of WestVac Biopharma Co., Ltd. located in the Knowledge City Innovative Vaccine Production Base of Guangzhou Economic Development Zone. With the 5000L combined production lines to be built soon for recombinant insect cell protein vaccine and nasal spray vaccine, it will have an annual production capacity of 500 million vaccine doses.

WestVac Biopharma Co., Ltd., the parent company, is an innovative biopharmaceutical company integrating RD, production and sales of vaccines. From 2021 to 2022, WestVac Biopharma was successfully selected on the Unicorn Companies list for two consecutive years. Coviccine┬« –Recombinant COVID-19 Vaccine (Sf9 cell) developed by WestVac Biopharma has demonstrated satisfactory safety and immunogenicity in clinical trial with 70.95% protective efficacy against Omicron subvariants, which is one of the most effective vaccines in the prevention of symptomatic cases of COVID-19 with Omicron subvariants in the world. In December 2022, Coviccine┬« has been approved by the national authority for emergency use and has already been tendered and supplied for vaccination in multiple provinces. Meanwhile, the Recombinant Variant (Sf9 cell) COVID-19 vaccine developed by WestVac Biopharma has recently received Clinical Trial Approval by NMPA, phase I/II clinical trials will start soon.

Photo – https://mma.prnewswire.com/media/2005535…

View original content: https://www.prnewswire.com/news-releases/westvac-biopharmavacuna-trivalente-de-proteina-recombinante-covid-19-contra-subvariantes-xbb1-5-y-ba5–301751316.html